|
Volumn 4, Issue 2, 2014, Pages 138-139
|
Dasatinib-letrozole gets split verdict
a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AROMATASE INHIBITOR;
DASATINIB;
EXEMESTANE;
FULVESTRANT;
LETROZOLE;
TAMOXIFEN;
ACUTE LYMPHOBLASTIC LEUKEMIA;
BREAST CANCER;
BREAST METASTASIS;
CELL PROLIFERATION;
ESTROGEN RECEPTOR POSITIVE BREAST CANCER;
HUMAN;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AROMATASE INHIBITORS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
NITRILES;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
THIAZOLES;
TREATMENT OUTCOME;
TRIAZOLES;
|
EID: 84896738004
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2013-181 Document Type: Note |
Times cited : (6)
|
References (0)
|